Limits...
Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT.

Schreiter NF, Bartels AM, Froeling V, Steffen I, Pape UF, Beck A, Hamm B, Brenner W, Röttgen R - Radiol Oncol (2014)

Bottom Line: The standard of reference included histopathology or clinical verification based on follow-up examinations.In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p = 0.01).Out of these 21 patients 14 patients were operated.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

ABSTRACT

Background: To evaluate the clinical efficacy of In-111 DTPA octreotide SPECT/CT and Ga-68 DOTATOC PET/CT for detection of primary tumors in patients with either neuroendocrine tumor of unknown primary (NETUP) or clinically suspected primary NET (SNET).

Patients and methods: A total of 123 patients were included from 2006 to 2009, 52 received Ga-68 DOTATOC PET/CT (NETUP, 33; SNET, 19) and 71 underwent In-111 DTPA octreotide SPECT/CT (50; 21). The standard of reference included histopathology or clinical verification based on follow-up examinations.

Results: In the NETUP group Ga-68 DOTATOC detected primaries in 15 patients (45.5%) and In-111 DTPA octreotide in 4 patients (8%) (p < 0.001); in the SNET group, only 2 primaries could be detected, all by Ga-68 DOTATOC. In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p = 0.01). Out of these 21 patients 14 patients were operated.

Conclusion: Ga-68 DOTATOC PET/CT is preferable to In-111 DTPA octreotide SPECT/CT when searching for primary NETs in patients with NETUP but should be used with caution in patients with SNET.

No MeSH data available.


Related in: MedlinePlus

(A–C) Insulinoma presenting as a hyperperfused (A) Ga-68 DOTATOC positive lesion (B) in the pancreatic head (C). In the In-DTPA octreotide scintigraphy (D) and SPECT (E) performed 3 days earlier no lesion could be found.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230553&req=5

f1-rado-48-04-339: (A–C) Insulinoma presenting as a hyperperfused (A) Ga-68 DOTATOC positive lesion (B) in the pancreatic head (C). In the In-DTPA octreotide scintigraphy (D) and SPECT (E) performed 3 days earlier no lesion could be found.

Mentions: Examples of patients who underwent both examinations are shown in figures 1–3.


Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT.

Schreiter NF, Bartels AM, Froeling V, Steffen I, Pape UF, Beck A, Hamm B, Brenner W, Röttgen R - Radiol Oncol (2014)

(A–C) Insulinoma presenting as a hyperperfused (A) Ga-68 DOTATOC positive lesion (B) in the pancreatic head (C). In the In-DTPA octreotide scintigraphy (D) and SPECT (E) performed 3 days earlier no lesion could be found.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230553&req=5

f1-rado-48-04-339: (A–C) Insulinoma presenting as a hyperperfused (A) Ga-68 DOTATOC positive lesion (B) in the pancreatic head (C). In the In-DTPA octreotide scintigraphy (D) and SPECT (E) performed 3 days earlier no lesion could be found.
Mentions: Examples of patients who underwent both examinations are shown in figures 1–3.

Bottom Line: The standard of reference included histopathology or clinical verification based on follow-up examinations.In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p = 0.01).Out of these 21 patients 14 patients were operated.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

ABSTRACT

Background: To evaluate the clinical efficacy of In-111 DTPA octreotide SPECT/CT and Ga-68 DOTATOC PET/CT for detection of primary tumors in patients with either neuroendocrine tumor of unknown primary (NETUP) or clinically suspected primary NET (SNET).

Patients and methods: A total of 123 patients were included from 2006 to 2009, 52 received Ga-68 DOTATOC PET/CT (NETUP, 33; SNET, 19) and 71 underwent In-111 DTPA octreotide SPECT/CT (50; 21). The standard of reference included histopathology or clinical verification based on follow-up examinations.

Results: In the NETUP group Ga-68 DOTATOC detected primaries in 15 patients (45.5%) and In-111 DTPA octreotide in 4 patients (8%) (p < 0.001); in the SNET group, only 2 primaries could be detected, all by Ga-68 DOTATOC. In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p = 0.01). Out of these 21 patients 14 patients were operated.

Conclusion: Ga-68 DOTATOC PET/CT is preferable to In-111 DTPA octreotide SPECT/CT when searching for primary NETs in patients with NETUP but should be used with caution in patients with SNET.

No MeSH data available.


Related in: MedlinePlus